SG11201400289SA - Glycosylated polypeptide and drug composition containing said polypeptide - Google Patents
Glycosylated polypeptide and drug composition containing said polypeptideInfo
- Publication number
- SG11201400289SA SG11201400289SA SG11201400289SA SG11201400289SA SG11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide
- composition containing
- drug composition
- glycosylated
- glycosylated polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011192202 | 2011-09-04 | ||
| PCT/JP2012/072380 WO2013032011A1 (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201400289SA true SG11201400289SA (en) | 2014-05-29 |
Family
ID=47756483
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201601324VA SG10201601324VA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
| SG11201400289SA SG11201400289SA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201601324VA SG10201601324VA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9422357B2 (en) |
| EP (1) | EP2752424B1 (en) |
| JP (1) | JP6178238B2 (en) |
| KR (1) | KR102031998B1 (en) |
| CN (2) | CN107522779B (en) |
| AU (1) | AU2012302636B2 (en) |
| BR (1) | BR112014004784A2 (en) |
| CA (1) | CA2847334C (en) |
| DK (1) | DK2752424T3 (en) |
| IN (1) | IN2014CN02399A (en) |
| RU (1) | RU2624034C2 (en) |
| SG (2) | SG10201601324VA (en) |
| TW (1) | TWI662966B (en) |
| WO (1) | WO2013032011A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201601324VA (en) * | 2011-09-04 | 2016-03-30 | Glytech Inc | Glycosylated polypeptide and drug composition containing said polypeptide |
| WO2013032012A1 (en) | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | Glycosylated polypeptide and drug composition containing said polypeptide |
| CN111855827B (en) * | 2019-04-24 | 2022-09-16 | 岛津企业管理（中国）有限公司 | Method for determining polysaccharide protein binding site binding rate in polysaccharide protein binding vaccine |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000259A (en) * | 1975-06-16 | 1976-12-28 | American Home Products Corporation | Cyclic dodecapeptide analogs of somatostatin and intermediates |
| US4380953A (en) | 1978-09-11 | 1983-04-26 | Filper Corporation | Transfer mechanism in a peach pitter |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4280953A (en) * | 1979-11-08 | 1981-07-28 | The Salk Institute For Biological Studies | Glycosylated analogs of somatostatin |
| US4316891A (en) * | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
| LU85269A1 (en) * | 1984-03-26 | 1985-10-14 | Techland S A | NOVEL SOMATOSTATIN COMPOUNDS, PROCESS FOR THEIR SYNTHESIS, PREPARATION FOR VETERINARY USE CONTAINING SAID COMPOUNDS AND PROCESS FOR THE TREATMENT OF ANIMALS |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| HU906340D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| AU6655496A (en) * | 1995-08-11 | 1997-03-12 | Novo Nordisk A/S | Method for preparing polypeptide variants |
| US5750499A (en) * | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| FI965181A (en) * | 1996-12-20 | 1998-06-21 | Map Medical Technologies Oy | Polyalcohol peptide derivatives |
| JP3385947B2 (en) | 1998-01-05 | 2003-03-10 | 松下電器産業株式会社 | Bulk feeder |
| EP1198565A1 (en) * | 1999-07-07 | 2002-04-24 | Maxygen Aps | A method for preparing modified polypeptides |
| US20030036181A1 (en) * | 2000-06-30 | 2003-02-20 | Okkels Jens Sigurd | Peptide extended glycosylated polypeptides |
| WO2002085418A2 (en) * | 2001-04-23 | 2002-10-31 | Mallinckrodt Inc. | Tc and re labeler radioactive glycosylated octreotide derivatives |
| EP2322533A1 (en) | 2001-06-19 | 2011-05-18 | Otsuka Chemical Co., Ltd. | Process for producing sugar chain asparagine derivative |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| TWI330641B (en) | 2002-12-24 | 2010-09-21 | Yasuhiro Kajihara | Sugar chain asparagine derivatives |
| CN100413889C (en) * | 2002-12-24 | 2008-08-27 | 大塚化学株式会社 | Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain, and processes for producing these |
| JP4790271B2 (en) | 2002-12-26 | 2011-10-12 | 康宏 梶原 | Three-branched sugar chain asparagine derivatives, the sugar chain asparagine, the sugar chain, and methods for producing them |
| AU2004209371B2 (en) | 2003-02-04 | 2008-05-01 | Glytech, Inc. | Process for producing sugar chain asparagine derivative |
| JPWO2004101619A1 (en) * | 2003-05-15 | 2006-10-26 | 塩野義製薬株式会社 | Rational design and synthesis of functional glycopeptides |
| CN1829742B (en) | 2003-07-28 | 2010-06-09 | 大塚化学株式会社 | Aminated complex-type sugar chain derivatives and process for the production thereof |
| KR100604994B1 (en) * | 2004-01-30 | 2006-07-26 | 한국생명공학연구원 | A novel Hansenula polymorpha gene coding for ?1,6- mannosyltransferase and process for the production of recombinant glycoproteins with Hansenula polymorpha mutant strain deficient in the same gene |
| TWI342880B (en) | 2005-07-19 | 2011-06-01 | Otsuka Chemical Co Ltd | Method for producing sugar chain derivatives, and sugar chain derivatives |
| US20070025910A1 (en) * | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
| SG178797A1 (en) * | 2007-06-19 | 2012-03-29 | Otsuka Chemical Co Ltd | Oligosaccharide chain added glp-1 peptide |
| WO2009103965A1 (en) | 2008-02-19 | 2009-08-27 | Asterion Limited | Modified linkers |
| WO2009153960A1 (en) * | 2008-06-17 | 2009-12-23 | 大塚化学株式会社 | Glycosylated glp-1 peptide |
| EP2294080A2 (en) * | 2008-06-27 | 2011-03-16 | Novo Nordisk Health Care AG | N-glycosylated human growth hormone with prolonged circulatory half-life |
| WO2013032012A1 (en) | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | Glycosylated polypeptide and drug composition containing said polypeptide |
| SG10201601324VA (en) * | 2011-09-04 | 2016-03-30 | Glytech Inc | Glycosylated polypeptide and drug composition containing said polypeptide |
-
2012
- 2012-09-03 SG SG10201601324VA patent/SG10201601324VA/en unknown
- 2012-09-03 CN CN201710964257.2A patent/CN107522779B/en active Active
- 2012-09-03 KR KR1020147008130A patent/KR102031998B1/en active IP Right Grant
- 2012-09-03 DK DK12828271T patent/DK2752424T3/en active
- 2012-09-03 CN CN201280053754.2A patent/CN103930441B/en active Active
- 2012-09-03 AU AU2012302636A patent/AU2012302636B2/en active Active
- 2012-09-03 BR BR112014004784A patent/BR112014004784A2/en not_active Application Discontinuation
- 2012-09-03 WO PCT/JP2012/072380 patent/WO2013032011A1/en active Application Filing
- 2012-09-03 CA CA2847334A patent/CA2847334C/en active Active
- 2012-09-03 SG SG11201400289SA patent/SG11201400289SA/en unknown
- 2012-09-03 IN IN2399CHN2014 patent/IN2014CN02399A/en unknown
- 2012-09-03 JP JP2013531454A patent/JP6178238B2/en active Active
- 2012-09-03 EP EP12828271.2A patent/EP2752424B1/en active Active
- 2012-09-03 US US14/342,359 patent/US9422357B2/en active Active
- 2012-09-03 RU RU2014112046A patent/RU2624034C2/en active
- 2012-09-04 TW TW101132259A patent/TWI662966B/en active
-
2016
- 2016-07-08 US US15/205,960 patent/US9937264B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6178238B2 (en) | 2017-08-09 |
| SG10201601324VA (en) | 2016-03-30 |
| US20140336116A1 (en) | 2014-11-13 |
| IN2014CN02399A (en) | 2015-06-19 |
| CN107522779B (en) | 2021-10-26 |
| RU2624034C2 (en) | 2017-06-30 |
| US9937264B2 (en) | 2018-04-10 |
| JPWO2013032011A1 (en) | 2015-03-23 |
| US9422357B2 (en) | 2016-08-23 |
| CA2847334A1 (en) | 2013-03-07 |
| WO2013032011A1 (en) | 2013-03-07 |
| BR112014004784A2 (en) | 2017-03-21 |
| RU2014112046A (en) | 2015-11-27 |
| US20170157260A1 (en) | 2017-06-08 |
| TWI662966B (en) | 2019-06-21 |
| AU2012302636A1 (en) | 2014-03-20 |
| KR20140059829A (en) | 2014-05-16 |
| CN107522779A (en) | 2017-12-29 |
| EP2752424A4 (en) | 2015-04-22 |
| EP2752424A1 (en) | 2014-07-09 |
| CA2847334C (en) | 2020-09-01 |
| KR102031998B1 (en) | 2019-10-14 |
| CN103930441A (en) | 2014-07-16 |
| AU2012302636B2 (en) | 2016-09-15 |
| TW201315478A (en) | 2013-04-16 |
| DK2752424T3 (en) | 2019-11-18 |
| CN103930441B (en) | 2017-11-17 |
| EP2752424B1 (en) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262667B (en) | An isolated polynucleotide encoding a polypeptide and a pharmaceutical composition comprising the isolated polynucleotide | |
| SG10201601327RA (en) | Glycosylated polypeptide and drug composition containing said polypeptide | |
| HK1199889A1 (en) | Relaxin fusion polypeptides and uses thereof | |
| ZA201305504B (en) | Compositions containing glycosylated antibodies and uses thereof | |
| EP2728002A4 (en) | Heterodimerized polypeptide | |
| EP2718317A4 (en) | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof | |
| IL279676A (en) | Recombinant proteins and their therapeutic uses | |
| EP2738255A4 (en) | Erap1-derived peptide and use thereof | |
| SG11201405578TA (en) | Pharmaceutical composition containing peptide | |
| ZA201302113B (en) | Caspofungin composition | |
| EP2775831A4 (en) | Pharmaceutical compositions and uses thereof | |
| ZA201207375B (en) | Stabilized pharmaceutical composition | |
| SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
| EP2666482A4 (en) | Particle composition and pharmaceutical composition using particle composition | |
| HK1198910A1 (en) | Pharmaceutical composition comprising ebastine and fluticasone | |
| SG11201400289SA (en) | Glycosylated polypeptide and drug composition containing said polypeptide | |
| SG11201401071YA (en) | Glycosylated polypeptide and pharmaceutical composition containing same | |
| IL221501A (en) | Pharmaceutical composition comprising myramistin | |
| EP2743252A4 (en) | Tetravalent platinum complex and pharmaceutical composition containing same | |
| PL2918267T3 (en) | Particulate pharmaceutical composition | |
| EP2751129A4 (en) | Protein p14 with anti-cancer and anti-allergy activity and pharmaceutical composition comprising the same | |
| ZA201309537B (en) | Pharmaceutical composition comprising fexofedine |